Engflag

Navan

Quick links to important sections

Navan

Navan_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Navan

Property Description
Active Ingredient Thiothixene (INN)
Form Capsules, Oral Concentrate (Solution)
Pharmacological Class First-Generation Antipsychotic (Typical)
Common Use Symptomatic management of schizophrenia
Origin Synthetic thioxanthene derivative

What Type of Medicine is Navan (Thiothixene)?

Navan is the former brand name for the prescription-only medication Thiothixene, which is classified as a First-Generation Antipsychotic (FGA), widely known as a Typical Antipsychotic. This categorization identifies it as a conventional neuroleptic agent used for managing severe disturbances in thought and behavior.

The core of the drug is the synthetic compound Thiothixene, which belongs to the unique thioxanthenes chemical series. This thioxanthene derivative is notable for being considered a high-potency FGA. Navan is a single-ingredient product, and the active component is primarily available for oral administration as capsules or an oral concentrate.

Composition, Form, and General Purpose

Thiothixene is formulated using the base compound (INN) along with excipients, and the active molecule exists as a mixture of chemical isomers, cis-Thiothixene and trans-Thiothixene.

The overall goal of this medication, which is clinically recognized in the U.S. and internationally, is to provide potent antipsychotic activity to achieve neurological stabilization in patients. Its primary purpose is the symptomatic management of schizophrenia. This stabilization helps to reduce the severe cognitive disorganization and agitation associated with psychotic disorders in affected adults and adolescents (aged 12 and older).

What side effects are possible with Navan?

Possible Side Effects and Safety Information

The safety profile of Thiothixene (formerly Navan) is established through regulatory classification of adverse reactions by system, frequency, and severity, as documented in official government sources like the FDA Prescribing Information and NIH MedlinePlus.

Adverse Reactions and Systemic Classification

The most frequently documented effects often involve the central and autonomic nervous systems. These common adverse reactions include drowsiness (which may subside with continued use), Extrapyramidal Symptoms (EPS) such as restlessness (akathisia) and muscle spasms (dystonia), dry mouth, blurred vision, and constipation. Cardiovascular effects such as orthostatic hypotension (dizziness or fainting upon standing) and tachycardia are also listed.

Rare, but officially documented, effects have involved the hematologic system (e.g., leukopenia, agranulocytosis risk) and endocrine system (e.g., hyperprolactinemia, which may lead to missed periods or breast enlargement).

Serious Safety Warnings

The label mandates warnings for clinically significant adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), a potentially fatal syndrome characterized by hyperpyrexia and severe muscle rigidity, and Tardive Dyskinesia (TD), a movement disorder with a risk that increases with long-term use. The official labeling also includes a Boxed Warning stating that antipsychotic agents are associated with an increased risk of death in older adults with dementia-related psychosis, a population for which this medicine is not approved.

Safety-Related Restrictions and Duration Patterns

Contraindications prohibit use in individuals experiencing circulatory collapse, comatose states, severe CNS depression, or blood dyscrasias. Acute movement disorders (dystonia) are noted to occur more frequently in males and younger age groups and are most common during the first few days of treatment. Exposure during the third trimester of pregnancy is noted to place the newborn at risk for extrapyramidal or withdrawal symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Navan (thiothixene) by detailing specific clinical manifestations and required emergency actions.

Documented Overdose Presentations: Overdosage may present with symptoms of Central Nervous System (CNS) depression, including drowsiness and coma. Serious neurological signs include extrapyramidal symptoms (EPS) such as rigidity, tremor, and muscle twitching, often accompanied by excess salivation and difficulty swallowing (dysphagia).

Severe, potentially life-threatening outcomes include convulsions (seizures), circulatory collapse, and hypotension (low blood pressure), alongside the risk of cardiac irregularities like QT prolongation and Torsade de pointes.

Management Constraint Immediate Action & Monitoring
Treatment is symptomatic and supportive. Contact a poison control center or emergency room at once if an overdose is suspected.
Epinephrine must not be used for hypotension due to the risk of paradoxical further lowering of blood pressure. Urgent medical help is required immediately if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Official labeling also notes that Neonates exposed during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery, sometimes requiring intensive care support. The patient must be kept under careful observation due to the risk of respiratory difficulty associated with severe EPS.

Therapeutic Uses of Navan

What Navan Treats: Main Uses and Benefits

This medication is commonly used to treat the symptoms of schizophrenia, a condition where functional stability becomes affected and periods of heightened distress are common. It is primarily relevant for easing the burden of core psychotic features like delusions and hallucinations, as well as managing symptoms of severe agitation and psychomotor excitement.

This medication is commonly used during phases when symptoms become more noticeable, such as acute episodes, when supportive symptom management is appropriate. It is also relevant for long-term support across chronic conditions characterized by recurrent or episodic symptom patterns in adults and adolescents (aged 12 and older).

“It is applied in clinical settings that involve acute or unstable symptom patterns to provide supportive assistance for stabilization.”

It assists with maintaining functional stability and plays a role in managing the risk of recurrent acute episodes, contributing to improved day-to-day comfort.

Quick Fact: Relief for Positive Psychotic Features

Managing Symptom Clusters

This medicine helps to moderate high levels of behavioral disorganization and severe psychomotor excitement to support neurological stabilization. By addressing associated patterns like apathy or withdrawal, it assists with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily with these difficult manifestations.

Regulatory References

  1. NIH MedlinePlus overview of Thiothixene

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility for Navan (thiothixene) as defined by authoritative regulatory documents.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents 12 years of age and older for the symptomatic management of schizophrenia.
Populations for whom use is not recommended Children under 12 years of age; safe conditions for use have not been established.
Populations for whom use is contraindicated Patients with Circulatory Collapse, Comatose States, Central Nervous System (CNS) Depression, Blood Dyscrasias, or known Hypersensitivity to the drug.
Age-related eligibility rules Use in elderly patients with dementia-related psychosis is not approved due to an increased risk of death (Boxed Warning exclusion).
Condition-specific eligibility rules Use requires extreme caution in patients with a history of Convulsive Disorders or those in a state of Alcohol Withdrawal.
Pregnancy and lactation eligibility status Pregnancy: Safe use has not been established; only use when expected benefits exceed possible risks. Neonates exposed during the third trimester are at risk for withdrawal symptoms.

Eligibility Classifications

The regulatory label defines precise exclusions and restrictions based on patient status, primarily from the U.S. Food and Drug Administration (FDA) Prescribing Information:

  • Contraindicated: Absolute prohibition for patients with critical physiological issues (e.g., CNS depression, circulatory collapse).
  • Not Approved / Not Recommended: Exclusion for specific age groups and conditions (e.g., children under 12, dementia-related psychosis).
  • Conditional Use: Required for patients with underlying risks such as cardiovascular disease or a history of seizures, where treatment may proceed but only with extreme caution.

Connection to the overall eligibility profile: The official regulatory documents strictly define eligibility by first establishing absolute prohibitions based on critical co-existing conditions. Beyond these contraindications, use is explicitly constrained by age and is entirely excluded for children under 12 and for elderly patients with dementia-related psychosis. The remaining eligible populations must be assessed for conditional use if they have specific risk factors like a history of convulsive disorders or cardiovascular disease.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Official regulatory documentation for thiothixene (Navan) describes several documented interaction patterns primarily involving pharmacodynamic reinforcement and alterations in clearance. These statements are derived exclusively from government drug labels.

Documented Interaction Categories

Interaction Type Interacting Agents / Classes Formal Outcome as Documented
Pharmacodynamic CNS Depressants (e.g., sedatives) Risk of additive depressant effects and hypotension.
Pharmacodynamic Anticholinergic Drugs (e.g., atropine) Potential for additive anticholinergic effects.
Pharmacokinetic Hepatic Enzyme-Inducing Agents (e.g., carbamazepine) Increased clearance of thiothixene, leading to reduced exposure.
Substance Alcohol Caution regarding additive depressant effects.

Regulatory Restrictions and Specific Constraints

The most specific restriction concerns the management of acute low blood pressure. Regulatory labels prohibit the use of the vasopressor agent epinephrine to treat hypotension in a patient taking thiothixene. This is due to a documented interaction where the combination may result in the reversal of epinephrine's effect, causing a paradoxical further lowering of blood pressure.

Additionally, caution is required when co-administering with other hypotensive agents due to the risk of excessive hypotension.

For specific populations, official documentation notes that thiothixene is associated with an increased risk of death when used to treat elderly patients with dementia-related psychosis, a population for whom this medicine is not approved.

Mechanism of Action

How Navan Works: Mechanism of Action

Navan, or Thiothixene, exerts its action primarily through the antagonism (blockade) of receptors in the Central Nervous System ( CNS). Its foundational mechanism involves the D2 dopamine receptor ( DRD2), where its high-affinity binding suppresses dopaminergic signaling. This action occurs mainly within the mesolimbic pathway, resulting in a net reduction in dopaminergic output within these specific CNS circuits.

Simultaneously, the molecule engages in broad receptor modulation by blocking the 5- HT2 A serotonin receptor and the histamine H1 receptor. These complementary actions contribute to the drug's overall profile by influencing central arousal levels and neural excitability. Additionally, the drug blocks peripheral alpha1-adrenergic receptors, which affects the autonomic nervous system and vascular tone.

This high-affinity blockade is non-selective across all regions. An unavoidable consequence is D2 receptor occupancy in the nigrostriatal pathway and the tuberoinfundibular pathway, leading to altered signaling in motor feedback loops and dysregulation of dopamine-dependent endocrine functions as intrinsic changes to the physiological status of these pathways.

Dosage and Administration Information

Thiothixene, formerly known as Navan, is administered via two primary routes: oral (capsules or oral concentrate) and intramuscular (IM) injection. The IM route is reserved for rapid control of acute behavioral disturbances and requires a prompt transition to the oral dosage form as soon as possible.

The dosing and frequency are governed by the patient's clinical state.

Administration Detail Official Guideline
Oral Dosing Range Usual maintenance is 20 mg to 30 mg daily, administered in divided doses. The maximum approved dose is 60 mg per day.
Frequency Pattern Typically administered in divided doses two or three times daily (BID or TID). The dose may transition to a single daily dose for long-term maintenance.

For proper intake, all oral forms should be administered with food or fluid. A specific preparation step applies to the oral concentrate: it must be diluted immediately before consumption in 2 to 4 ounces of liquid, such as water or juice.

The use of the medicine has restrictions based on age. A lower initial dosage and slower adjustment process (titration) are advised for older or debilitated patients. Furthermore, the medication is not recommended for use in pediatric patients under 12 years of age because safety has not been established in that group. The overarching principle for long-term use is to maintain the smallest effective dose for the shortest possible duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Navan (Thiothixene)

This section summarizes the published clinical evidence regarding Navan (thiothixene), drawing only on data from official regulatory reviews and scientific studies. The focus is on the type of research conducted and what was observed, without offering personal advice or clinical recommendations.

Evidence for Use in Acute Schizophrenia

The clinical evidence for Navan is based on short-term randomized controlled trials (RCTs) and comparative studies. These studies included adult populations in research contexts involving fluctuating or unstable symptoms. Researchers explored short-term symptom changes, monitoring outcomes related to episodic or acute changes and capturing phases of heightened symptom activity.

These research trials examined how overall symptoms were measured using clinical instruments like the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS). Findings describe patterns observed in the studies related to how symptoms evolved and global clinical status during defined time intervals, typically lasting a few weeks. This research describes findings related to conditions associated with acute or disruptive episodes.

Evidence in Long-Term and Maintenance Settings

Research examining the long-term patterns of Navan use was evaluated in observational settings monitoring daily-life functioning and maintenance studies. These studies were observed in adult populations requiring continuous support for a condition characterized by fluctuating or episodic manifestations. Research monitored long-term outcomes, such as the frequency of relapse or re-exacerbation of symptoms and overall rates of medication discontinuation.

Although long-term use was studied for, long-term effects are not fully established. The evidence base for maintenance treatment includes observations where data for long-term outcomes remains insufficient when compared to short-term data.

Research for Use in Specific Age Groups

Specific research also was evaluated in adolescents aged 12 and older with schizophrenia. These studies monitored symptom changes in this younger age group, observing responses over defined time intervals. However, the data for adolescents are considered to be based on modest sample sizes and a limited number of dedicated studies. The results apply only to the populations studied; specifically, research has not explored use in children younger than 12 years of age.

Key Studies & References

  1. Thiothixene: MedlinePlus Drug Information
  2. Psychosis and schizophrenia in adults: prevention and management (NICE Guideline CG178)

Frequently Asked Questions (FAQ)

Common questions about Navan (FAQ)

Q: How quickly does Navan start to work?

Official labeling contains a warning that the medicine may impair mental and physical abilities, particularly during the first few days of therapy. This warning describes the typical timing of some effects observed shortly after starting the medicine.

Q: Are there any foods or drinks to avoid while taking Navan?

Regulatory guidance notes that all oral forms should be taken with food or fluid. Additionally, caution is advised regarding the use of alcohol because it can cause additive depressant effects when combined with this medicine. No specific foods or non-alcoholic drinks are listed to avoid in the official documents.

Q: Will I feel different right away after starting Navan?

The official product information notes that effects on mental and physical abilities, such as feeling different or less alert, may be experienced, particularly during the first few days of therapy. This is a common pattern of initial experience for the medicine.

Q: How long do most people stay on Navan? (Duration)

According to the official prescribing principles, the overarching goal of treatment is to maintain the smallest effective dose for the shortest possible duration. The actual length of time a patient stays on the medicine is determined by individual clinical need and continuous professional assessment.

Q: Can Navan cause weight gain?

Weight gain is a documented adverse reaction that has been reported by some patients using the medicine. This is part of the established safety profile noted in regulatory drug information.

Q: What happens if I forget to take a dose of Navan?

Official guidance on a missed dose indicates that if the lapse is noticed soon after the scheduled time, the dose can be taken. If it is nearly time for the next scheduled dose, the guidance describes skipping the missed dose and resuming the regular schedule. Regulatory information advises against taking a double dose.

Q: Do studies show Navan helps with mood swings?

Official clinical research focuses on outcomes related to the symptomatic management of schizophrenia, and studies describe patterns related to the evolution of unstable symptoms. Official regulatory labeling does not specifically cite studies showing effects on general 'mood swings.'

Q: Is Navan considered a controlled substance?

The medicine is classified as a prescription-only drug. Official regulatory classification indicates that it is not scheduled as a controlled substance under the U.S. Controlled Substances Act.

Q: Does Navan interact with herbal supplements like St. John's Wort?

The medicine carries a regulatory warning regarding interactions with other agents that increase the clearance of the drug from the body. Official information indicates that some herbal products, such as St. John's Wort, may fall into this category.

Q: What common side effects usually go away after a few weeks on Navan?

Official documents note that drowsiness is a common adverse reaction that is often experienced when starting the medicine. The documents specifically mention that this effect may subside with continued use over time.

Q: Can Navan be used while breastfeeding?

The manufacturer has not established a recommendation for the use of the medicine during lactation. This is because it is officially unknown if the active ingredient is excreted into human milk.

Q: What is the risk of dependence or addiction with Navan?

Regulatory information indicates that when stopping this medicine, a gradual reduction (tapering) is advised to avoid possible physical withdrawal symptoms and potential rebound effects. The drug is not classified as a controlled substance with a primary risk of addiction.

Q: Why is Navan sometimes prescribed for conditions other than the main one?

The primary approved indication for the medicine is the symptomatic management of schizophrenia. However, the drug may also be used by prescribers to manage certain symptoms of related psychotic disorders.

Q: Can taking Navan affect my ability to drive?

The official label contains a prominent caution that the medicine may impair the mental and physical abilities needed to perform potentially hazardous tasks. These tasks include driving a car or operating machinery.

Q: Is Navan used to treat anxiety?

The approved use of the medicine, according to the official FDA indications, is for the symptomatic management of schizophrenia (a mental illness). It is not officially indicated by the FDA for the treatment of generalized anxiety.

Q: What kind of monitoring is needed while taking Navan? (General monitoring)

Official warnings indicate that monitoring for signs of blood dyscrasias (disorders of the blood components) is sometimes warranted. The label also contains warnings regarding potential effects such as CNS depression. The need for specific testing is based on individual risk factors as determined by a healthcare professional.

Q: Why do some people say Navan didn't work for them?

Clinical trials explore how symptoms evolved during defined treatment time intervals, typically lasting a few weeks. These studies show that patient response is variable, and the drug may not produce the desired effects for every individual.

Q: Is Navan a new medicine or has it been around for a while?

The medicine, Thiothixene, is a First-Generation Antipsychotic and has a long regulatory approval history. Its former brand name, Navan, indicates it is a conventional drug that has been in use for a long period of time.

Q: Is it mandatory to have regular blood tests while taking Navan?

Official prescribing information states that a periodic blood count assessment may be warranted in patients with specific risk factors, such as a preexisting low white blood cell count. The label does not state that regular blood tests are a mandatory requirement for every patient.

Q: Can Navan be taken at any time of day?

The drug is typically prescribed either in divided doses throughout the day or, for long-term use, as a single daily dose. The specific time of day for taking the medicine is often decided by the prescriber, taking into account factors like the common side effect of drowsiness.

Q: Are there known interactions between Navan and common cold/allergy medicines?

Caution is advised when using the medicine alongside other drugs that may cause CNS depression or have anticholinergic effects. Official information indicates that these types of agents are often found in common cold or allergy medicines.

Q: Does Navan help with stress?

The approved use for the medicine, as documented in official regulatory sources, is for the symptomatic management of schizophrenia. The drug is not officially indicated for the treatment of general stress.

Q: What if Navan doesn't seem to be working after the first month?

Clinical trials explored short-term symptom changes over defined time intervals, typically lasting a few weeks. If a response is not observed within that time frame, a professional evaluation is appropriate to determine the next steps in treatment.

Q: Can Navan cause issues with short-term memory?

Official warnings state that the medicine may cause effects on the Central Nervous System (CNS) that can impair mental abilities. This is related to the possibility of experiencing drowsiness and other CNS effects.

Q: Is Navan a drug that requires gradual stopping?

When discontinuing this class of medicine, the prescribing information advises a gradual reduction (tapering). This measure is recommended to avoid the risk of physical withdrawal symptoms and potential rebound effects.

How should Navan be stored and disposed of?

How to Store and Dispose of Navan (Thiothixene)?

Official Storage Conditions

Thiothixene, formerly branded as Navan, must be stored within the temperature range of 20 C to 25 C (68 F to 77 F), adhering to Controlled Room Temperature guidelines. The product must be protected from freezing.

Both the capsules and the oral concentrate solution must be stored in a tightly closed container. The oral concentrate specifically requires storage in a light-resistant container. This medicine must be kept out of the reach of children to prevent accidental exposure.

Disposal Requirements

Unused or expired Thiothixene should be disposed of in accordance with local regulations and pharmaceutical waste handling procedures. Regulatory guidance advises against pouring the medicine down a sink or flushing it down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Navan found in:

A-Z Index: